Humacyte prices $50M public offering
Analysis based on 9 articles · First reported Jun 10, 2026 · Last updated Jun 11, 2026
The public offering by Humacyte is expected to raise $50 million, which will directly impact its financial position by providing capital for commercialization, pipeline development, and general corporate purposes. This influx of capital could positively influence investor confidence in Humacyte's ability to fund its growth initiatives. The involvement of Barclays, BTIG, and Titan Partners as joint book-running managers indicates market support for the offering.
Humacyte, a commercial-stage biotechnology company, announced and priced an underwritten public offering of 47,619,048 shares of its common stock at $1.05 per share, aiming to raise $50 million in gross proceeds. The offering also includes an option for underwriters, including Barclays, BTIG, and Titan Partners, to purchase an additional 7,142,857 shares. The net proceeds will be used to fund the commercialization of Symvess, support the planned filing of a Biologics License Application supplement for a hemodialysis indication, develop product candidates in its pipeline, and for general working capital. The offering is expected to close around June 12, 2026, subject to customary closing conditions. A shelf registration statement was previously filed with the United States — United States Securities and Exchange Commission (SEC) and declared effective.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard